European Psychiatry - Volume 41 - April 2017

272 / 916

S268 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S238–S302
into intervention (n = 15) or control (n = 14) arm, including 736
patients (73% psychotic disorder, 63% male, 48 ± 13 years). The
intervention aimed to improve the obesogenic environment using a
small change approachwith a focus on nutrition and physical activ-
ity. Primary outcomewas waist circumference (WC) after three and
twelve month’s intervention. Secondary outcomes were BMI and
metabolic syndrome.
Results General linear mixed models adjusted for age, gen-
der, housing facility and antipsychotic medication showed that
WC significantly decreased with 1.51 cm (95%CI = −2.99;−0.04,
Cohen’s d = 0.07) in the intervention group compared to con-
trol group after three months and tended to remain lower with
1.28 cm (95%CI = −2.79; 0.23, Cohen’s d= 0.06) after twelvemonths.
Metabolic syndrome Z-score decreased after three months with
0.225 SD (95% CI = −0.4038;−0.096, Cohen’s d = 0.20), mainly due
to lower fasting glucose and WC. No significant effects were found
on BMI.
Conclusion A small change approach targeting the obesogenic
environment of SMI residential patients reduces cardiometabolic
risk.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0475
Paliperidone palmitate and quality of
life in schizophrenia
N.B. Juan Carlos ∗ , B. Girela , A. Maria Angeles
Hospital de Motril, Department of Psychiatry, Granada, Spain
∗ Corresponding author.
There is growing interest in the study of the quality of life of
mental disorders in general, and particularly in schizophrenia. The
quality of life is defined by the world health organization as the
perception that an individual has of his place in existence, in the
context of culture and value system in which they live and in rela-
tion to its objectives, their expectations, their rules, their concerns.
Paliperidone palmitate is a depot anti-psychotic treatmentmonthly
application is indicated for maintenance treatment of schizophre-
nia in adult patients. In this work the quality of life in 5 subjects
with a diagnosis of paranoid schizophrenia (less than 10 years of
diagnosis) is evaluated, all males, aged between 42 and 45 years
and with poor adherence to oral treatment. The patients received
an average of paliperidone palmitate 100mg/month. We evaluate
the quality of life at baseline and after 3months – BREF quality of life
(WHOQOL – BREF) Scale Quality of Life (QOLS) and WHO was used.
The results showed significant improvements in major QOLS scale
in all subjects. There were no significant differences in total score
WHOQL – BREF scale, but if there was improvement in the scores
of some subscales. They no side effects evaluated in the UKU scale.
The quality of life in schizophrenic patients can be affected by the
presence of, particularly cognitive and negative clinical symptoms.
New treatments as paliperidone palmitate improve adherence and
have fewer side effects can improve the perceived quality of life.
However, they need more extensive studies double-blind evalua-
tion.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0476
Effect of long-acting injectable
aripiprazole in glucose and lipids:
A 1 year study
M. Juncal Ruiz ∗ , O. Porta Olivares ,
B. Fernández-Abascal Puente , M. Gómez Revuelta ,
R. Landera Rodríguez , G. Pardo de Santayana Jenaro ,
L. Sánchez Blanco Pérez Herrera Abejas Díez
J.L. García Egea
1 Hospital Universitario Marqués de Valdecilla, Psychiatry,
Santander, Spain
2 Hospital Universitario de Álava-Sede Santiago, Psychiatry,
Vitoria-Gasteiz, Spain
3 Hospital Universitario Virgen del Rocío, Psychiatry, Sevilla, Spain
∗ Corresponding author.
Introduction Atypical anti-psychotics are associated with an
impaired in glucose and lipids homeostasis.
Aims To evaluate, the effect in lipids and glucose levels after
switching to long-acting injectable (LAI) aripiprazole.
Methods This was a prospective, observational, 1 year study car-
ried out in 125 outpatients with schizophrenia who were clinically
stabilized but a switching to another anti-psychotic was indicated.
We measured basal levels of glucose and lipids at the time to start
the study and 1 year after switching to LAI-aripiprazole.
Results Inbasal analyticwe observed these abnormalities: hyper-
glycemia (16.7%), high-levels of LDL-cholesterol (33.3%), low-levels
of HDL-cholesterol (39%) and hypertrygliceridemia (22.2%). One
year after switching to LAI-aripiprazole we found: glucose levels
were normalized in all patients; levels of LDL-cholesterol were
lower in 66.7% (in 33.3% levels were normalized) and they were
higher in 16.7% (in 11% marked a change from normal to abnormal
parameters); levels of HDL-cholesterol were lower in 23.3% and
higher in 32.2% (in 11% levels were normalized); and finally, levels
of tryglicerides were higher in 66.7% (in 8% marked a change from
normal to abnormal parameters) and in 16.7% they were lower (in
7.3% levels were normalized).
Conclusions LAI-aripiprazole has a beneficial effect in glucose and
cholesterol levels. Although, it usually increases tryglicerides levels,
only in seven cases there was a change from normal to abnormal
parameters. Our study suggests that LAI-aripiprazol could be an
alternative in patients with schizophrenia who have high levels of
glucose and lipids related with atypical anti-psychotics treatment.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0477
Risk factors related to homicide in
Moroccan patients with schizophrenia
A. Kachouchi ∗, D.S. Majda , D.S. Said , P.A. Imane ,
P.M. Fatiha , P.A. Mohamed , P.A. Fatima
1 University hospital Mohammed VI, Department Of Psychiatry,
Marrakech, Morocco
2 University hospital Mohammed VI, Clinical research unit,
Mohammed VI university hospital/Community Medicine and Public
Health department, Marrakech, Morocco
∗ Corresponding author.
Background The relationship between schizophrenia and homi-
cide is complex and cannot be reduced to a simple causal link.
Objectives The objectives of this study were to describe the
characteristics of homicide in Moroccan patients suffering from
schizophrenia and to determine the correlated socio-demographic,
clinical and toxic variables.
Methods The study included two groups of patients with a
DSM-IV diagnosis of schizophrenia who attended the “Ibn Nafis”
university psychiatric hospital of Marrakech in Morocco. The first
group was composed of 30 patients hospitalized for homicide in
the forensic unit between the first January 2005 and the 31st of
August 2015. The second group included 90 patients without any
criminal record. These two groups have been matched according
to age and gender. Demographic, clinical and therapeutic variables
were analyzed and compared between the two groups.
Results The mean of age in the first group was 37.03 and in
the second group was 31.4. No significant difference was found